Sitravatinib - Mirati Therapeutics

Drug Profile

Sitravatinib - Mirati Therapeutics

Alternative Names: MG-516; MG91516; MGCD-0516; MGCD-516

Latest Information Update: 25 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MethylGene
  • Developer Columbia University; Mirati Therapeutics; University Health Network
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Axl receptor tyrosine kinase inhibitors; Eph family receptor antagonists; Platelet-derived growth factor receptor antagonists; Proto oncogene protein c met inhibitors; Proto oncogene protein c ret inhibitors; Proto oncogene protein c-kit inhibitors; Proto-oncogene protein c-mer inhibitors; Receptor protein-tyrosine kinase antagonists; RON protein inhibitors; TIE 2 receptor antagonists; Tropomyosin-related kinase antagonists; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Liposarcoma; Non-small cell lung cancer; Renal cell carcinoma; Soft tissue sarcoma; Urogenital cancer
  • Phase I Solid tumours; Squamous cell cancer

Most Recent Events

  • 22 Oct 2018 Updated efficacy data from a phase II trial in Non-small cell lung cancer released by Mirati Therapeutics
  • 22 Oct 2018 Mirati Therapeutics plans a pivotal phase III trial for Non-small cell lung cancer (Combination therapy, Second-line therapy or greater) in first half of 2019
  • 21 Oct 2018 Phase I trial in Solid tumours is still ongoing in South Korea and USA (NCT02219711)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top